Aimmune Therapeutics Inc (AIMT) Receives $49.00 Consensus Target Price from Analysts

Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) have been assigned an average recommendation of “Hold” from the ten brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $49.00.

AIMT has been the topic of several research analyst reports. Wedbush lowered their price target on Aimmune Therapeutics from $80.00 to $76.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 19th. Cantor Fitzgerald began coverage on Aimmune Therapeutics in a research report on Sunday, December 9th. They issued an “overweight” rating and a $23.75 price target on the stock. Credit Suisse Group reissued a “buy” rating and set a $40.00 target price on shares of Aimmune Therapeutics in a research report on Tuesday, January 15th. BidaskClub downgraded Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 17th. Finally, Goldman Sachs Group began coverage on Aimmune Therapeutics in a research report on Thursday, December 13th. They set a “neutral” rating and a $32.00 target price on the stock.

Shares of NASDAQ:AIMT opened at $23.11 on Monday. The stock has a market capitalization of $1.44 billion, a PE ratio of -6.30 and a beta of -0.13. Aimmune Therapeutics has a 52-week low of $20.94 and a 52-week high of $36.12.

Several large investors have recently bought and sold shares of AIMT. Bank of New York Mellon Corp lifted its position in Aimmune Therapeutics by 9.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 171,766 shares of the biotechnology company’s stock worth $4,619,000 after buying an additional 14,283 shares in the last quarter. Russell Investments Group Ltd. grew its position in shares of Aimmune Therapeutics by 32.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 25,251 shares of the biotechnology company’s stock worth $690,000 after purchasing an additional 6,215 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Aimmune Therapeutics by 6.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 145,966 shares of the biotechnology company’s stock worth $3,982,000 after purchasing an additional 9,289 shares in the last quarter. BlackRock Inc. boosted its position in shares of Aimmune Therapeutics by 9.3% during the 3rd quarter. BlackRock Inc. now owns 3,982,580 shares of the biotechnology company’s stock worth $108,644,000 after acquiring an additional 338,740 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in shares of Aimmune Therapeutics during the 3rd quarter worth approximately $426,000. Institutional investors own 73.85% of the company’s stock.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

See Also: Net Margin – Understanding the Different Kinds of Profit

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.